SafeHeal
SafeHeal is a leading innovator in the field of digestive surgery. Its CE-marked Colovac device is a unique endoluminal bypass sheath placed in the colon following colorectal resection. It suppresses the contact of fecal content with the colorectal anastomotic site in order to significantly improve patient recovery after colorectal surgery, without the need for an ostomy. It is seamless, minimally invasive and fully reversible. It can remain in place until the body’s natural healing and tissue repair processes are complete.
Sector
Medical Devices
Strategies
MD Start & Capital
Status
Live
Website
www.safeheal.com
Antoine Papiernik
Chairman & Managing Partner, Sofinnova Partners
Anne Osdoit
Partner, Sofinnova Partners - MD Start Strategy
Related News
SafeHeal Receives Breakthrough Device designation for Colovac Endoluminal Bypass Sheath
SafeHeal appoints medical device industry veteran Chris Richardson as Chief Executive Officer
SafeHeal announces successful launch of pivotal study for Colovac endoluminal bypass sheath
SafeHeal closes €40 million financing co-led by Sofinnova Partners and Genesis MedTech to finance its Colovac device through a pivotal clinical trial in the United States
SafeHeal obtains CE-mark for Colovac, its novel endoluminal bypass sheath
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.